Hemogenyx Shares Jump On Promising Data From Blood Cancer Therapy

(Alliance News) - Hemogenyx Pharmaceuticals on Wednesday said recent testing showed one of its ...

Alliance News 15 January, 2020 | 1:23PM
Email Form

(Alliance News) - Hemogenyx Pharmaceuticals on Wednesday said recent testing showed one of its therapies to be effective against acute myeloid leukaemia, a type of blood cancer.

Shares in the company were 18% higher at 2.25 pence each in London on Wednesday afternoon.

Hemogenyx is developing a form of a chimeric antigen receptor cell, cells which have been genetically modified, in order to treat acute myeloud leukaemia.

In vitro testing found its HEMO-CAR cells were able to programme existing T-cells, a type of immune cell, "to identify and destroy" acute myeloid leukaemia cells.

In vitro testing means it was performed in a controlled laboratory environment like a test tube or petri dish.

Next, Hemogenyx will perform a similar study, this time in-vivo, so on a whole living organism. The study will be performed on humanised mice developed by Hemogenyx's Immugenyx subsidiary.

Chief Executive Vladislav Sandler said: "We are encouraged by this new data which demonstrates our continuing progress in the development of novel treatments for blood cancers such as AML. The development of HEMO-CAR-T expands Hemogenyx's pipeline and advances it into a cutting-edge area of cell-based immune therapy.

"We are excited to have developed another product candidate that should, if successful, provide a new and potentially effective treatment for blood cancers for which survival rates are currently very poor."

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Hemogenyx Pharmaceuticals PLC 2.20 GBX -2.22 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites